Carbomed Medical Solutions is the company behind breathe ilo – the world’s first fertility tracker that uses breath analysis to identify a woman’s ovulation pattern and fertile window in an easy and comfortable way. Now, only six months after launching in the UK, the Austrian femtech start-up has announced £2.5M(€3M) in funding continue its expansion in the UK market.
With help from the integrated smartphone app’s features, women planning to conceive can effectively and naturally determine optimal fertility periods. Female users breathe into the device for a minute every day, while the data is recorded and transmitted to the app. The company is committed to helping women improve their chances of having a child. This is demonstrated in the 50% of their product sale price that is reinvested into technological research in female fertility and menstrual cycles. Founded in 2013, breathe ilo is the brainchild of leading gynaecologist Professor Dr. Ludwig Wildt and Dr. Horst Rüther.
Led by AWS Gründerfonds (one of the largest Austrian Venture Capital funds), the recent investment will enable breathe ilo to continue developing its product and expand its supply in the UK. “Even though many industries have been hit hard by the pandemic, the fertility market has exploded, fuelled by our focus on the importance of our families and loved ones. Thanks to our expansion into the UK, we reached our annual 2020 revenue goal within the third quarter, which was a significant milestone for the company,” adds Lisa Krapinger, CMO at breathe ilo.
Carbomed Medical Solutions is a former participant of the EIT Health Start-ups Meet Pharma programme. During the programme in 2020, the company extended its CO2 measurement technology to provide support in the detection and monitoring of Portable Interstitial Lung Disease (ILD).
“Additionally, we are working on licensing further product features and preparing for a launch in other English
speaking markets at a later date,” added Bastian Rüther, breathe ilo’s CEO.